CARL ZEISS MEDITEC AG 
Currency effects also affected earnings per share at the beginning of the year: due primarily to the negative results from currency hedges, which are offset by positive effects in the operating result, consolidated profit after non-controlling interests amounted to around € 16.7 million, corresponding to a decline of 8.8 percent compared with the year-ago figure.
'The quarter was characterized by positive currency effects and, within the regions, by very heterogeneous development. Thanks to our balanced presence, we achieved a good overall result once again,' says Dr. Ludwin Monz, President and CEO of Carl Zeiss Meditec AG. 'Unlike other industries, we can also report largely stable development, for the time being, in our high-growth business in China.'
Key Figures by Business Segment at a Glance
Once again, the Surgical Ophthalmology strategic business unit (SBU) achieved the highest growth rates. Revenue climbed by 13.6 percent in the reporting period, compared with the year-ago quarter, to € 92.6 million (prior year: € 81.6 million). Even after adjustment for currency effects, this growth was still in the double digits, at 10.7 percent. Surgical workstations for optimized workflow in ophthalmology, and intraocular lenses, were once again in high demand, as were systems for optical biometry.
The Ophthalmic Systems SBU increased its revenue by 7.5 percent in the reporting period, to € 98.6 million (prior year: € 91.7 million). After adjustment for currency effects, however, this growth would only have amounted to 0.7 percent.
The Microsurgery SBU generated revenue of € 71.3 million, which corresponds to an increase of 5.2 percent compared with the year-ago figure of € 67.8 million; adjusted for currency effects, revenue is on a par with the prior year.
Revenue by Region
The three global regions made varying contributions to the Company's revenue; once again, the greatest growth came from the Asia/Pacific (APAC) region, even after adjusting for currency effects.
In the EMEA region (Europe, Middle East and Africa), significant contributions to growth came in particular from Germany and the United Kingdom; development in Southern Europe was mixed. On balance, revenue in the EMEA region increased by 4.2 percent, to EUR 90.2 million (prior year: € 86.5 million).
Revenue in the Americas region benefited from the strong U.S. dollar and - even on a currency-adjusted basis - from a positive trend in Latin America. Overall, revenue growth of 10.1 percent to € 88.8 million was achieved (prior year: € 80.6 million). Adjusted for currency effects, the region would have recorded a slight decline of 1.4 percent,because the development of the U.S. business remained subdued.
The APAC region once again recorded the highest growth, increasing its revenue by 13.1 percent, to € 83.6 million(prior year: € 73.9 million). After adjustment for currency effects, this corresponds to growth of 9.1 percent.
According to President and CEO, Dr. Ludwin Monz, the first quarter has not changed expectations for the fiscal year: 'We shall continue to strive for growth that is at least on a par with market growth, and for an EBIT margin in the range of 13 to 15 percent.'
Revenue by Strategic Business Unit
| Figures in EUR '000 | 3 Months 2014/15 | 3 Months 2015/16 |
Change from prior year |
Change from prior year¹ |
| Ophthalmic Systems | 91,742 | 98,634 | +7.5% | +0.7% |
| Surgical Ophthalmology | 81,570 | 92,644 | +13.6% | +10.7% |
| Microsurgery | 67,778 | 71,323 | +5.2% | -0.1% |
¹ adjusted for currency effects
Revenue by Region
| Figures in EUR '000 | 3 Months 2014/15 | 3 Months 2015/16 |
Change from prior year |
Change from prior year¹ |
| EMEA | 86,549 | 90,195 | +4.2% | +4.5% |
| Americas | 80,639 | 88,815 | +10.1% | -1.4% |
| APAC | 73,902 | 83,591 | +13.1% | +9.1% |
¹ adjusted for currency effects
Press Contact:
Jann Gerrit Ohlendorf
Director Corporate Communications
Carl Zeiss Meditec AG
Phone: +49 3641 220-331
Fax: +49 3641 220-332
press.meditec@zeiss.com
Sebastian Frericks
Director Investor Relations
Carl Zeiss Meditec AG
Phone: +49 3641 220-116
investors.meditec@zeiss.com
Carl Zeiss Meditec AG
Carl Zeiss Meditec AG (ISIN: DE 0005313704), which is listed on TecDAX of the German stock exchange, is one of the world's leading medical technology companies. The Company supplies innovative technologies and application-oriented solutions designed to help doctors improve the quality of life of their patients. It provides complete packages of solutions for the diagnosis and treatment of eye diseases, including implants and consumable materials. The Company creates innovative visualization solutions in the field of microsurgery. The medical technology portfolio of ZEISS is rounded off by promising future technologies such as intraoperative radiation therapy. With approx. 2,900 employees worldwide, the Group generated revenue of € 1,040 million in fiscal year 2014/2015 (to 30 September).
The Group's head office is in Jena, Germany, and it has subsidiaries in Germany and abroad; more than 50 percent of its employees are based in the USA, Japan, Spain and France. The Center for Application and Research (CARIn) in Bangalore, India and the Carl Zeiss Innovations Center for Research and Development in Shanghai, China, strengthen the Company's presence in these rapidly developing economies. Around 35 percent of Carl Zeiss Meditec AG's shares are in free float. The remaining approx. 65 percent are held by Carl Zeiss AG, one of the world's leading groups in the optical and optoelectronic industries.
For more information visit our website at:
www.zeiss.com/med
Number: 0015-2016-ENG OP
Number of Words: 1076
Number of Characters: 9222
Carl Zeiss Meditec AG issued this content on 12 February 2016 and is solely responsible for the information contained herein. Distributed by Public, unedited and unaltered, on 12 February 2016 08:23:32 UTC
Original Document: http://applications.zeiss.com/C1256A770030BCE0/WebViewTopNewsAllE/05B52D8718CF17BDC1257F570016BA7B?OpenDocument
